I have read the article published by Cure et al. [1] with great interest. They investigated the effects of increased levels of bilirubin on the mean platelet volume (MPV) and other hematological parameters. They have found that MPV level was lower in the Gilbert's syndrome patients than the normal population. In this study, the selected Gilbert's syndrome patients had no risk factors that could accelerate the atherosclerosis process, such as diabetes, hypertension, hyperlipidemia or smoking. These factors can also increase MPV [2] . This is an interesting study. On the contrary, we want to make minor criticism about this study from the methodological aspect.
In the methods section, they did not mention the tube that the blood sample was collected for whole blood count. This is very important. MPV increases over time in EDTA-anticoagulated samples and this increase has been shown to be proportional with the delay in time between sample collection and laboratory analysis. [3] . With impedance counting, the MPV increases over time as platelets swell in EDTA, with increases of 7.9% within 30 min having been reported and an overall increase of 13.4% over 24 h, although the majority of this increase occurs within the first 6 h [3] . The recommended optimal measuring time of MPV is 120 min after venipuncture [4] . For reliable MPV measurement, the potential influence of anticoagulant on the MPV must be carefully controlled, either using an alternative anticoagulant (such as citrate) or standardizing the time delay between sampling and analysis (less than 2 h). This situation is not clear in the study.
They speculated that increased bilirubin, known to be a potent antioxidant, decreases oxidative stress and the chronic inflammation, which in turn decreases MPV. In one study, it has been shown that regular flavonoid antioxidants' intake decreases MPV [5] . I think that bilirubin, a potent antioxidant, acts in a similar way and decreases MPV. It is well known that there is a close association between oxidative stress and atherothrombosis. Experimental and clinical studies showed the pivotal role played by reactive oxidant species in the mechanism of platelet activation. This effect is achieved via multiple pathways, including enhanced formation of isoprostanes [6] . These findings raise the question of whether the patients with cardiovascular diseases with higher MPV benefit from natural antioxidants or not. Recently, cardiovascular disease prevention guidelines recommended regular daily intake of fruits and vegetables because of their positive effect on cardiovascular morbidity and mortality. The natural antioxidants such as fruits and vegetables might decrease platelet activation and MPV and with this mechanism, cardiovascular morbidity and mortality might decrease. Lupus anticoagulant testing -sometimes mixing is required: potential for false negatives without mixing studies [1] [2] [3] . APS is associated with significant thrombosis and recurrent foetal morbidity and mortality [1, 2] , and its diagnosis fundamentally requires the finding of positive antiphospholipid antibody (aPL) test result(s) [3] , among which lupus anticoagulant appears to be of primary importance. The detection of lupus anticoagulant is in turn fraught with many difficulties [3, 4] .
We were therefore very interested to read the recent report on lupus anticoagulant testing in this journal by Hong et al. [5] . These authors reported on the association of thrombotic events with results of lupus anticoagulant testing according to whether or not mixing tests were employed. They characterized patients as lupus anticoagulant positive with or without mixing studies, according to reactivity profiles with the dilute Russell Viper Venom Time (dRVVT) and silica clotting time (SCT) using screen and confirmation reagents. They found the group of patients who were lupus anticoagulant positive by mixing studies to show a higher lupus anticoagulant activity and a higher thrombotic risk than the group of patients found to be lupus anticoagulant positive by assays not using mixing. However, even the mixingnegative lupus anticoagulant positive group carried a significant risk of thrombosis. They therefore advocated a place for lupus anticoagulant investigations that did not incorporate a mixing step. The authors also cited previous work that supported performance of nonmixing tests because mixing might lead to loss of 'weak' lupus anticoagulant activity [6] [7] [8] . Although these particular studies did not advocate complete removal of mixing tests, rather highlighting a limitation of mixing, and suggesting that some lupus anticoagulants can be found without them, we have continued to note a general move away from mixing studies in normal laboratory practice, for example including participants of our external quality assessment (EQA) programme [9] . Accordingly, before all laboratories abandon mixing studies entirely, we feel it appropriate to place some caveats on the perception that mixing tests are somehow unnecessary.
First, Hong et al. [5] indicated that the latest lupus anticoagulant guidelines [10] 'state that the integrated test does not have to incorporate the mixing test'. This, however, is not a statement of fact, but rather a theoretical consideration. It is likely that a journal-imposed word limit (2000 words maximum permitted) on International Society on Thrombosis and Haemostasis (ISTH) Scientific and Standardisation Committee (SSC) official communications restricted much of the detail that the authors would have wanted to include within the lupus anticoagulant guidelines [10] . Thus, although these guidelines seem to say that lupus anticoagulant mixing is optional, a later published clarification confirmed the authors' strong support for mixing studies [11] , even with so-called 'integrated tests'. This lupus anticoagulant guideline clarification publication was prompted by an early report from our group [12] describing a case of a very strong lupus anticoagulant test sample, in which both dRVVT screen and confirm tests were equally prolonged when tested as a neat (nonmixed) sample, thus yielding a normal dRVVT screen/confirm ratio, and therefore leading to a false impression of 'negative' lupus anticoagulant.
This leads to our second caveat, the concept that not performing mixing studies may lead to a false-negative lupus anticoagulant finding. Although Hong et al. [5] considered the possibility of false-negative lupus anticoagulant by performance of mixing studies and dilution of a weak lupus anticoagulant, as previously reported [6] [7] [8] , they failed to consider the alternate, namely the possibility of false-negative lupus anticoagulant by nonperformance of mixing studies and due to the presence of a strong lupus anticoagulant. In the lupus anticoagulant guidelines clarification response [11] to our original correspondence report [12] of the case of a strong lupus anticoagulant sample being falsely 'lupus anticoagulant negative' by virtue of a normal dRVVT screen/confirm ratio, the suggestion was raised that our observations could be explained by the lack of some cofactor when using the native patient plasma. Although such a cofactor effect is otherwise well reported [13] , and justifies use of mixing tests in its own right, our own explanation of reported findings [12] was related to the likely inability of the level of (supposedly excess) phospholipid present in modern confirmation dRVVT reagents to neutralize the very strong lupus anticoagulant present in such strongly lupus anticoagulant positive samples. In support of this, the lupus anticoagulant sample did substantially prolong the dRVVT screen clotting time, which would not have occurred should this sample lack a required cofactor; however, the dRVVT confirmation clotting time was similarly prolonged, and thus, the resultant dRVVT screen/confirm lupus anticoagulant ratio was normal. In further support of our explanation was the observation that one lupus anticoagulant reagent showed better sensitivity to the strong lupus anticoagulant, with shortening of the dRVVT confirmation clotting time even with the neat (unmixed sample), suggesting a higher level of (excess) phospholipid present in this reagent.
An elevated screen test result using undiluted plasma, accompanied by a similarly elevated confirm test result, and together with an elevated mixing test result (using the screen assay) does not fulfil the criteria for the presence of a lupus anticoagulant because phospholipid dependence has not yet been demonstrated with these results. Thus, alternative approaches would be required in order to identify the lupus anticoagulant, potentially including using another dRVVT reagent to show phospholipid dependence; increasing the phospholipid concentration in the confirm reagent; additionally performing confirm tests on a 1 : 1 mix; or assaying the plasma with other venom reagents such as taipan and ecarin venoms, in which the latter is unaffected by lupus anticoagulants. Furthermore, an elevated screen accompanied by an apparently negative mixing test should still receive a confirm test in laboratories who do not use integrated testing.
The question 'How often are strong lupus anticoagulant samples falsely identified as lupus anticoagulant negative due to laboratories not performing mixing studies?' remains largely unanswered. In our original correspondence [12] and a subsequent full report [14] , over 90% of laboratories that performed mixing studies correctly identified the lupus anticoagulant positive sample, whereas over 90% of laboratories that did not perform mixing studies incorrectly identified this sample as lupus anticoagulant negative. This particular lupus anticoagulant positive sample was so strong that titration of the sample to 1/32 dilution in normal plasma was required to obtain the highest dRVVT screen/confirm ratio (see Fig. 1a [9, 12, 14, 15] ).
We also know that our originally described case [12, 14] does not represent a unique occurrence, as we observed a similar phenomenon in a more recent EQA exercise [9] . This second lupus anticoagulant positive sample was despatched as both a neat sample (LUP11-08a) and as a sample diluted 1 : 2 in normal plasma (LUP11-08b). About 10% of our EQA participant laboratories now perform lupus anticoagulant testing using 'integrated testing without mixing', and interestingly, many of these reported a false lupus anticoagulant negative finding for the neat sample, due again to the observance of normal dRVVT screen/confirm ratios (see Fig. 1b ) [9] . The Westmead laboratory has also recently identified a third strong lupus anticoagulant positive case, giving this unusual pattern of increasing dRVVT ratio with increasing dilution into normal plasma (Fig. 1c) .
The third and final caveat relates to the idea that strongly positive lupus anticoagulant may represent a more serious adverse event threat (e.g. thrombosis) than 'weak' lupus anticoagulant. As reported by Hong et al. [5] , samples that were lupus anticoagulant positive by mixing reflected stronger lupus anticoagulant activity and were also more strongly associated with thrombosis than those that were negative by mixing. It is also well established that lupus anticoagulant is a stronger risk factor for adverse events such as thrombosis than other 'solid phase' assays such as anticardiolipin assays [17] . One proposed reason to explain this finding is that lupus anticoagulant (clotting) assays are relatively 'under-sensitive' to aPL, so that only higher-titre and more clinically relevant forms of aPL are detected by these assays [18] . Thus, although weak lupus anticoagulant may be relevant to the thrombosis story, they may not be as 'important' as strong lupus anticoagulant. Nevertheless, this concept is tempered by
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the fact that lupus anticoagulants can react differently with different reagents, so that one lupus anticoagulant apparently weak using one assay can appear strong in another. Furthermore, an antibody apparently low in titre at presentation may gain potency later on, or vice versa, so 'classification of strength' based on one analytical event can be misleading, as may attempting to grade titre on the basis of results of any particular reagent.
In conclusion, that mixing of 'weak' lupus anticoagulant samples may lead to loss of lupus anticoagulant activity and give rise to 'false lupus anticoagulant negativity' seems to be often reported by laboratories [5] [6] [7] [8] and thus used as an argument to not perform lupus anticoagulant mixing tests. The most recent lupus anticoagulant guidelines [10] are not entirely clear regarding expert opinion in this area, but more recent clarification from authors of this guideline give strong support to the need for performance of mixing tests [11, 13] . Our own experience points to the need to perform lupus anticoagulant mixing studies at least whenever dRVVT screening tests are prolonged, because a false-negative lupus anticoagulant finding may ensure due to failure of current confirmation dRVVT reagent clotting times to correct, resulting in normal dRVVT ratios ( [9, 12, 14] and current report -see also Fig. 1 ). These findings hold significance for patients being investigated for APS, as a false-negative lupus anticoagulant finding may lead to false exclusion of APS, and thus withholding of appropriate therapy, which for APS includes extended anticoagulant therapy [19] .
The crucial point in lupus anticoagulant identification lies in the interpretation of test data and not just the final screen/confirm ratio. Both ISTH 2009 [10] and British Committee for Standards in Haematology (BCSH) 2012 [20] guidelines recommended percentage correction of screen ratio by confirm ratio as one of the two calculations for identifying phospholipid dependence; this may be a useful approach, as it 'forces' scrutiny of the screening test result, and subsequently the confirm result. Additional strategies to consider have been raised earlier in this correspondence and elsewhere [15, 16] . Finally, additional investigation of the potential lupus anticoagulant by novel methods such as thrombin generation could also be considered [21] .
